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The nuclear receptor peroxisome proliferator-activated receptor g (PPARg) is essential for placental
development. For insights into its functions in the placenta, we screened for PPARg-regulated genes by
integrating expression proﬁles of Pparg-null and Rxra-null placentas with those of WT and Pparg-null
trophoblast stem cells differentiated in the presence or absence of a PPARg agonist. Intersection of
these paradigms identiﬁed high-probability PPARg target genes. A few of these genes were previously
reported as PPARg targets in other tissues, but most are new in the context of either PPARg or placental
biology. Transcriptional proﬁling demonstrated a widespread role for the coactivator NCOA6/AIB3, but
not MED1/PBP, in PPARg-dependent placental gene expression. Spatial and temporal expression
analyses revealed that PPARg impacts genes in diverse trophoblast lineages and during different stages
of differentiation. We further validated the Ldhb gene, which encodes the H isoform of lactate
dehydrogenase, as a robust PPARg target in trophoblasts, and propose a hypothetical model that
integrates it with a network of PPARg-regulated genes into a novel pathway of placental fuel
metabolism. These ﬁndings offer insights not only into the placental functions of PPARg, but also into
unique, previously unsuspected biosynthetic functions of trophoblasts.
& 2012 Elsevier Inc. All rights reserved.Introduction
The placenta is essential for the survival and development of
all mammalian embryos, where it plays vital roles in transport of
gases, nutrients and waste between the mother and the fetus,
embryonic immune privilege and secretion of pregnancy
hormones. Placental aberrations underlie a wide range of fetal
and maternal pregnancy complications, including intrauterine
growth restriction, preeclampsia and pregnancy loss. Gene target-
ing studies in mice revealed numerous genes and pathways that
are indispensable for placental development and function
(Rossant and Cross, 2001). Detailed molecular and cellularll rights reserved.
rch Institute, Department of
ttsburgh, 204 Craft Avenue,
k).
manuscript.
ory and ﬁnalized atanalyses of these gene networks are required for better under-
standing of placental physiology and pathology.
One of the critical regulators of placental development is the
nuclear receptor peroxisome proliferator-activated receptor g
(PPARg) (Barak et al., 1999). Pparg-null placentas succumb to
lethal pleiotropic defects that span arrested differentiation and
lipid droplet depletion in labyrinthine trophoblasts, failed vascu-
larization, maternal blood pool breakdown, and erythrophagocy-
tosis by spongiotrophoblast (SpT) cells (Barak et al., 1999).
In addition, these primary placental defects precipitate severe
defects in embryonic heart development, which highlight the
long-range effects of the placenta beyond its critical functions at
the maternal-fetal barrier (Barak et al., 1999). Augmenting PPARg
activity in the placenta by treating pregnant mice with a PPARg
agonist interferes with placental development as well, causing
substantial thinning of the SpT layer and dilation of the labyr-
inthine vasculature (Schaiff et al., 2007). These effects stress the
importance of ﬁnely tuned PPARg activity in this tissue. The
robust induction of PPARg during differentiation of trophoblast
stem cells (TSC) further buttresses its tight association with
placental development (Shalom-Barak et al., 2004).
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adipogenesis, energy metabolism and inﬂammation, but none of
these functions provides clear mechanistic clues about its role in
placental development. Considering that PPARg is a transcription
factor, the deﬁnitive answer lies in the identities of its transcrip-
tional targets. Our earlier work identiﬁed Muc1 as a robust and
highly speciﬁc PPARg target gene in trophoblasts (Shalom-Barak
et al., 2004). Placental MUC1 protein is conﬁned to a single layer
of labyrinthine trophoblasts around the maternal blood pools,
which exhibit a partially penetrant dilated phenotype in Muc1-
deﬁcient placentas (Shalom-Barak et al., 2004). However, the
normal survival and growth of Muc1-null embryos imply that
other targets of PPARg transduce its essential placental functions.
Here, a robust microarray-based screening strategy, which inte-
grated non-redundant PPARg dependence paradigms, identiﬁes high-
conﬁdence PPARg targets. Presumptive targets exhibit diverse expres-
sion patterns in the whole placenta and in TSC, suggestive of
pleiotropic actions of PPARg in different placental compartments.
The vast majority of these genes are new in the contexts of both the
placenta and PPARg, and the few with known or deduced functions
regulate intermediary metabolism and multiple endocrine signaling
pathways. We further demonstrate that the transcription coactivator
AIB3 (Ncoa6) affects the expression of the majority of placental PPARg
target genes, whereas the coactivator PBP (Med1) plays little to no
role in their expression. Finally, we show that Ldhb, the gene encoding
heart lactate dehydrogenase, is a tightly regulated PPARg target in
trophoblasts, which in the context of additional metabolic targets
revealed here suggests a novel metabolic program in trophoblasts.
These ﬁndings offer important new insights into the physiological
functions and transcriptional mechanisms of PPARg in the placenta.Materials and methods
Mice
Ppargþ /mice (heterozygous for a lacZ knock-in allele; Barak
et al., 1999) were maintained on two separate inbred backgrounds:
129SvImJ (1 2 9) and C57BL6/J (B6; N414); placentas were
procured from embryo progeny of 129-Ppargþ / sires with B6-
Ppargþ / dams. Rxraþ / mice (Sucov et al., 1994) were backcrossed
onto B6 (N414); for placenta collection, B6-Rxraþ / females were
mated with 129/SvImJ-WT males and placentas were procured from
F2 embryo progeny of the resulting B6129F1-Rxraþ / mice. Med1þ /
 (Zhu et al., 2000) and Ncoa6þ / mice (Kuang et al., 2002) were
introgressed onto B6 for six and two generations, respectively, prior
to experiments. The Ppargyfp knock-in allele was generated using
standard recombinant DNA technology and introduced into the
Pparg locus by homologous recombination. Correct integration was
validated by Southern blots with probes external to the homology
arms of the vectors. Germ-line chimeras were established from one
correctly targeted Ppargyfp/þ ES cell line, and heterozygotes subse-
quently introgressed onto a B6 background for over eight genera-
tions (N48). To test in vivo effects of Rosiglitazone (Rosi) on
placental gene expression WT pregnant mice were fed from
E10.5E18.5 either powdered chow alone or powdered chow
containing 30 mg/kg/d Rosi (Schaiff et al., 2007). All mouse studies
at The Jackson Laboratory, Washington University and Magee-
Womens Research Institute were approved by the respective Animal
Care and Use Committees.
Placenta dissection and extraction
To collect WT and various mutant placentas pregnancies were
timed by copulation plugs (noon of the day of plug detection¼E0.5).
Placentas were separated from embryos, carefully trimmed of excessdecidual and yolk sac tissue, and kept individually refrigerated in
RNALater (Sigma). Genotypes were determined via PCR of DNA from
corresponding embryos, as described previously for each targeted
allele. Placentas with similar genotypes were pooled in groups of
three, and total RNA extracted using Tri-Reagent (Invitrogen).
Establishment and culture of trophoblast stem cells (TSC)
129-PparglacZ/þ males were mated with B6.129-Ppargyfp/þ
females, and blastocysts collected at E3.5 and plated individually
in 4-well dishes containing irradiated mouse embryo ﬁbroblasts
(MEF) in RPMI 1640 medium supplemented with 20% fetal bovine
serum, 25 ng/ml FGF4 and 1 mg/ml heparin, as described (Tanaka
et al., 1998). Blastocysts that attached to the substrate and
developed cellular outgrowths were dissociated with trypsin
and plated onto MEF in the same medium, which was changed
every other day. Cultures were passaged to fresh plates every four
days. Lines that exhibited morphological resemblance to TSC and
a consistent expansion pattern were genotyped by PCR, and
stocks were cryopreserved for further work.
For analysis of differentiated TSC, cells were passaged once in
the absence of feeder cells in the aforementioned medium,
supplemented with 70% embryonic ﬁbroblast conditioned
medium, and thereafter split for the various experiments. Cul-
tures were maintained for another 24 h in conditioned medium
and FGF4, and differentiation was induced for the designated
duration by withdrawing conditioned medium, FGF4 and heparin
from the medium. Where indicated, cultures were supplemented
with 1 mM Rosi for the duration of differentiation. RNA was
extracted with Tri-Reagent at the end of the indicated differentia-
tion periods.
Affymetrix microarray analysis
Placental and TSC RNA samples were treated with RNase-free
DNase and re-extracted. Biotin-labeled cRNA probes was gener-
ated according to manufacturer’s instructions (Affymetrix, Santa
Clara, CA) from: (i) Each of 3 pools of Pparg-null placentas vs. 3
litter-matched pools of WT placentas; (ii) Each of 3 pools of litter-
matched Rxra-null vs. WT placentas; (iii) Each of 3 pools of litter-
matched Med1-null vs. litter-matched WT and Ncoa6-null vs.
litter-matched WT placentas; (iv) The three WT TSC lines
described in this study were proﬁled after differentiation for
two or four days in the absence or presence of 1 mM Rosi (one
probe per condition); Pparg-null TSC were proﬁled only in the
presence of Rosi, to circumvent identiﬁcation of genes that are
induced by Rosi independent of PPARg. Each cRNA probe was
hybridized individually to a MOE430v2.0 GeneChip
TM
array in a
Fluidics Station 450 (Affymetrix). Arrays were imaged with a
GeneChip
TM
3000 Laser Confocal Slide Scanner, quantiﬁed using
GeneChip
TM
Operating Software v1.2 (Affymetrix), and expression
values summarized using the robust multichip average (RMA)
function. P values were assigned using analysis of variance
(ANOVA) (Churchill, 2004), except for the three Rosi-treated vs.
untreated WT TSC lines, which were compared pair-wise using
LIMMA (Smyth, 2004). False discovery rates (FDR; q-values) were
assigned to whole placenta data as described (Storey and
Tibshirani, 2003), after ﬁrst omitting all probe sets determined
as ‘absent’ by the Affymetrix MAS5.0 algorithm in all test samples.
Because of unsustainable variation, q-values for TSC data were
determined only for genes that passed fold-change (FC) and q
thresholds for WT vs. Pparg-null placentas. Data have been
deposited in NCBI’s Gene Expression Omnibus (GEO) database
(www.ncbi.nlm.nih.gov/geo), accession no. GSE39233. Abbre-
viated analysis ﬁles are available as Supplemental Tables S1 and
S2.
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RT and quantitative PCR (qPCR) were performed with RT and
SYBR Green PCR kits from Applied Biosystems according to
manufacturer speciﬁcations using an ABI 9700 thermal cycler.
Oligonucleotide pairs for individual genes (Table S3) were based
on Primer Bank whenever available or designed using the Primer3
shareware. Only reactions that yielded appropriate dissociation
curves are shown. qPCR reactions of placental RNA were normal-
ized to 36B4; reactions of RNA from TSC were normalized to
either the Dazap1 or Cwc15 genes, which were identiﬁed after
extensive screens as the least changed genes throughout differ-
entiation and Rosi treatment of all TSC lines. Relative expression
values were determined by the DDCt method (Livak and
Schmittgen, 2001). In situ hybridizations were performed as
described (Barak et al., 1999). Ppargþ / (lacZ-KI) parent pairs
were bred and concepti of each pregnancy were collected at E9.5,
ﬁxed in 4% paraformaldehyde and cryoembedded together in a
single block of OCT. Individual concepti in each embryo cohort
were genotyped by in situ hybridization of serial sections with
antisense riboprobes for Pparg and lacZ, identifying the WT and
Pparg-null allele, respectively. Additional serial sections were
hybridized with antisense probes for the indicated genes.
Reporter assays
DOTAP-mediated transfection of CV1 cells was performed in a
48-well format as described (Shalom-Barak et al., 2004). In short,
wells containing 50–70% conﬂuent CV1 cells were lipofected in
triplicates with combinations of nuclear receptors, reporters, and
CMV-lacZ controls at 25, 62.5, and 125 ng/well, respectively.
Lipofection medium was replaced after 5–8 h with DMEM
containing 2% charcoal and resin-stripped fetal calf serum and
the indicated ligand combinations. Cells were extracted 36–48 h
later, and assayed for luciferase and b-galactosidase activities.
Data show mean and standard deviation of normalized luciferase/
b-gal activity in triplicate wells from one representative experi-
ment out of at least two.
Chromatin immunoprecipitation (ChIP)
WT and Pparg-null TSC lines cultured were differentiated on
150 mm plates for four days in the presence of Rosi. Chromatin
was cross-linked, extracted, fragmented and precipitated essen-
tially as described (Hartman et al., 2002), except that the cells
were sonicated by four, instead of three bouts of 15 s. Custom-
made anti-PPARg antibodies used in the assay were described
previously (Kim et al., 2007). PCR fragments surrounding the
three putative PPREs in the Ldhb promoter and ﬁrst intron were
each ampliﬁed from 10% of either the entire immunoprecipitate
or 1% input in 30 cycles of 94 1C—15 s, 60 1C—30 s, 71.5 1C—55 s.
Forward and reverse primer sequences were, respectively: RE1–
50-AGC TCG AGG CCT TTT GGA GTG ATG TAT CAG TAG C-30/50-
TGA TTG GAA ACC CGA GAC GGG TCT ATC-30; RE2-50-GGT GTC
ACG GAA CTG AAC AAG CTC C-30/50-CCC CAC ATT CCC ATC TCC
TGT GG-30; RE3-50-GGG ACA AAA GAA AGA AAC GAG CTT GCT
TCA G-30/50-GGA ACC ACA TCT CAC CGA ATG CAG G-30.Results
Signiﬁcant misexpression overlaps between Pparg-null and Rxra-null
placentas
Genes whose placental expression is inﬂuenced by PPARg
were identiﬁed by Affymetrix microarray analysis of WT vs.Pparg-null placentas at E9.5. Statistical power and normalization
of stochastic sample differences were achieved by comparing
three pools of three Pparg-null placentas each to three litter-
matched pools of three WT placentas. Loss of Pparg expression
and a 4.5-fold reduction of Muc1 expression in microarrays of
Pparg-null placentas provided technical and conceptual conﬁ-
dence in the dataset. To focus on biologically meaningful changes
while minimizing false-positive calls, we deﬁned signiﬁcant
differences as those that exceeded 1.3-fold with a q-value of
r0.05. By these criteria, 481 genes were signiﬁcantly down-
regulated and 303 were signiﬁcantly up-regulated in Pparg-null
placentas.
Multiple phenotypic analogies between Rxra-null and Pparg-
null placentas (Sapin et al., 1997; Barak et al., 1999), topped by
the dramatic down-regulation of Muc1 in Rxra-null placentas
(Shalom-Barak et al., 2004), implicate RXRa as the primary
heterodimeric partner of PPARg in this tissue. Indeed, 203 of the
genes that signiﬁcantly decreased and 112 of those that increased
in Pparg-null placentas, corresponding to 42% and 37% of the
PPARg-dependent transcriptome, were also differentially
expressed in Rxra-null placentas (Fig. 1A). A signiﬁcant reduction
in Rxra mRNA levels and a threefold down-regulation of Muc1 in
microarrays of Rxra-null placentas (qo108) validated this arm
of the analysis. These relative ratios between mono- and co-
regulation by PPARg and RXRa were rather consistent over a
range of FC thresholds (Fig. 1A).Effects of PPARg dosage
The halving of Pparg and Muc1 levels in Ppargþ / placentas
(Barak et al., 1999; Shalom-Barak et al., 2004; Fig. 1B) is
consistent with the notion that at least some PPARg-regulated
genes respond to changes in PPARg gene dosage. In contrast,
genes that change only secondary to placental failure of Pparg-
null embryos, and not due to bone ﬁde changes in PPARg signaling
are not expected to be substantially inﬂuenced in the relatively
healthy Ppargþ / placentas. Accordingly, qPCR analyses were
performed to both validate microarray-inferred differential
expression of genes in Pparg-null placentas and determine their
relative levels in Ppargþ / placentas. Test samples included the
six RNA pools used in the original microarrays, their litter-
matched Ppargþ / placenta pools, and one additional pair of
litter-matched WT and Ppargþ / placenta pools. Table S4 lists all
tested genes and their expression values in Pparg-null and
Ppargþ / relative to WT placentas. Our analyses conﬁrmed the
down-regulation of 99/104 and the up-regulation of 40/43
microarray-identiﬁed genes in Pparg-null placentas. For practical
purposes, we deﬁned dosage-sensitivity as a statistically signiﬁ-
cant (Po0.05) expression change between WT and Ppargþ /
placentas that amounted to at least 25% of the corresponding
change in Pparg-null placentas. By this criterion, 44 of the 99
genes down-regulated in Pparg-null placentas (44%) displayed
dosage sensitivity. These included 37 of the 75 genes that were
also signiﬁcantly down-regulated in Rxra-null placentas (49%), as
opposed to 7 of the 24 genes (29%) that were unchanged in Rxra-
null placentas (Fig. 1C). Among the 39 genes that were up-
regulated in Pparg-null placentas, only 8 (21%) were signiﬁcantly
induced in Ppargþ / placentas. These were similarly divided
between RXRa-dependent and independent genes (5/27 [19%]
and 3/12 [25%], respectively) (Fig. 1C). Thus, dosage-sensitivity is
a more frequent attribute of genes that are down-regulated in
both Pparg-null and Rxra-null placentas, and less so of genes that
are either refractory to RXRa status or induced upon PPARg or
RXRa deﬁciency.
Fig. 2. Establishment of Pparg-null TSC. (A) Schematic structures of WT Pparg
and its two knock-in alleles used to derive TSC lines in this study. Numbers
designate respective exons and arrows show the orientations of knocked in
markers and drug selection cassettes. Both lacZ and yfp are in-frame with the
interrupted Pparg sequence. (B) Representative undifferentiated colonies of the
ﬁve studied TSC lines cultured in FGF4, heparin and MEF condition medium.
(C) Time-course Northern blot analyses of Pparg and its lacZ and yfp surrogates, the
stemness markers Eomes, Errb, and Cdx2, and the differentiated trophoblast
marker Mash2 (Ascl2) during differentiation of WT TSC Clone 2 and Pparg-null
clone gy20, respectively. 18S ribosomal RNA (rRNA) conﬁrms normalization.
Similar results were obtained with WT clones GFP-Trf and gy11 and Pparg-null
gy9 cells, validating the TSC identity of the new lines.
Fig. 1. Overlapping effects of PPARg, RXRa and NCOA6 on placental gene
expression. (A) Proportioned Venn diagrams show the numbers of overlapping
and mutant-speciﬁc probe sets down-regulated (left) or up-regulated (right) in
Pparg-null and/or Rxra-null placentas at qo0.05 by over 1.3 (top numbers),
1.5 (middle) and 2.0 (bottom). (B) qPCR analysis of Pparg and Muc1 expression
in WT, Ppargþ / and Pparg-null placentas. Each bar represents three-four pools of
three placentas of the corresponding genotype. (C) Proportioned Venn diagrams of
the relationships between PPARg dosage sensitivity and RXRa dependence of
representative genes down-regulated (left) or up-regulated (right) in Pparg-null
placentas. PPARg dosage sensitivity was deﬁned as differential expression in
Ppargþ / placentas that amounted to at least 25% of the differential expression in
Pparg-null placentas, as determined by qPCR. RXRa data are based on microarray
results. See Table S4 for the complete dataset. (D) Intersection of probe sets down-
regulated (left) or up-regulated (right) in microarrays of Pparg-null, Rxra-null and
Ncoa6-null placentas by more than 1.3 (top numbers), 1.5 (middle) and
2.0 (bottom), with qo0.05.
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Gene regulation by transcription factors depends on transcription
cofactors, which cement cooperative interactions within transcrip-
tional complexes, mediate interactions with the basal transcription
machinery and modify chromatin structure of target promoters. Of
the many cofactors whose interactions with PPARg have beendocumented extensively, two coactivators – PBP (Med1) and AIB3
(Ncoa6) – stand out in terms of the placental defects and early
lethality caused by their deﬁciency (Zhu et al., 2000; Kuang et al.,
2002). To assess the contributions of MED1 and NCOA6 to placental
PPARg-dependent gene expression, we proﬁled gene expression of
Med1-null and Ncoa6-null placentas following the same technical
and analytical principles established with Pparg-null and Rxra-null
placentas. Signiﬁcantly reduced levels of Med1 or Ncoa6 in the
microarrays of the respective null placenta pools provided technical
conﬁdence in both datasets. Against expectations, MED1 deﬁciency
had a minor effect on placental gene expression, with only 19 genes
down-regulated and 20 up-regulated by at least 1.3-fold, even with
a more relaxed FDR threshold of up to 0.1. None of the down-
regulated genes and only one of those that were up-regulated in
Med1-null placentas were concordantly affected in both Pparg-null
and Rxra-null placentas (see Table S1). In contrast, NCOA6 inﬂu-
enced the expression of over 2500 placental genes by 41.3-fold and
qo0.05, conﬁrming its major regulatory role in the tissue. Most
importantly, 43% (210/481) of the genes signiﬁcantly down-
regulated in Pparg-null placentas were signiﬁcantly suppressed in
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Fisher’s Exact Test was 15.12 with a P value of{2.2E-16. Moreover,
127 of the 203 transcripts that were down-regulated in both Pparg-
null and Rxra-null placentas (63%) were also down-regulated in
Ncoa6-null placentas (Fig. 1D; OR¼27.99; P{ 2.2E16). A smaller
proportion of the genes that were up-regulated in Pparg-null
placentas were signiﬁcantly induced in Ncoa6-null placentas (48/
303; 16%; OR¼6.15; Po2.2E16), and only 33% of those that were
co-up-regulated in Pparg-null and Rxra-null placentas recapitulated
this trait in Ncoa6-null placentas (OR¼14.25; P{ 2.2E16). These
data strongly suggest that while MED1 is a relatively minor
contributor to placental gene expression in general and to placental
PPARg-dependent transcription in particular, NCOA6 is a ubiquitous
co-activator of PPARg in the placenta.Fig. 3. Integration of in vivo and in vitro PPARg-dependence paradigms. (A) Heat m
with qo0.05 (left column), simulating their relative expression in Rxra-null placentas,
and Rosi-treated WT vs. Pparg-null TSC, each after two and four days of differentiation
sets below the Affymetrix MAS5.0 expression threshold in all TSC samples. (B) An anno
criteria. Abidance by each in vitro criterion at either day 2 or day 4 sufﬁced for inclusIntegration of in vivo and in vitro PPARg-dependence paradigms
The essential placental functions of PPARg are restricted to
trophoblasts (Barak et al., 1999). However, the complex cellular
composition of the placenta convolutes the interpretation of
expression proﬁles in the whole tissue. Therefore, we sought to
align the in vivo expression data with the effects of PPARg
manipulation in cultures of pure trophoblasts. TSC provide an
ideal platform for this type of analysis, as they are able to
differentiate into most trophoblast lineages. Moreover, PPARg is
potently induced and Muc1 is substantially up-regulated by the
PPARg agonist Rosi during TSC differentiation, demonstrating
preservation of key placental PPARg expression and activity
patterns in these cells (Shalom-Barak et al., 2004).ap of all probe sets that changed in Pparg-null placentas by greater than 1.3-fold
Rosi-treated vs. untreated WT TSC, untreated WT vs. Rosi-treated Pparg-null TSC,
. Black—individual differentials of less than 1.3-fold and/or q40.05. Grey—probe
tated distillation of the probe sets that abided by each of the PPARg-dependence
ion in this heat map.
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and gy20, derived from blastocysts carrying one Pparg::lacZ knock-
in (KI) allele (Barak et al., 1999) and a second, Pparg::yellow
ﬂuorescent protein (yfp) KI allele (Fig. 2A). We also established a
control WT TSC line, gy11, from sibling blastocysts. We studied
these cell lines alongside two previously established WT TSC
lines—GFP-Trf (Tanaka et al., 1998) and Clone 2 (Dr. T. Gridley,
The Jackson Laboratory, unpublished data). All ﬁve cell-lines
maintained a typical TSC morphology in the undifferentiated state
(Fig. 2B). Moreover, expression of the trophoblast stemness
markers Eomes, Cdx2, and Errb in the undifferentiated state and
their suppression within 1–2 day of differentiation alongside
induction of the Ascl2 (Mash2) gene authenticated the trophoblast
identity of the new lines (Fig. 2C, and data not shown). Impor-
tantly, Pparg or the knocked-in lacZ and yfp were induced during
differentiation of all WT or Pparg-null cell-lines, respectively
(Fig. 2C), conﬁrming the corresponding genotypes and indicating
that the Pparg locus is induced during TSC differentiation
independent of a functional PPARg protein. As with Ascl2, theTable 1
Genes abiding by all PPARc-dependence paradigms. A compilation of all genes who
placentas, Rosi-treated TSC and Pparg-null TSC. FC and statistical signiﬁcance values are
placentas. For Ppargþ / placentas, the ratio of FC to the FC in Pparg-null placentas is list
for Prdx4 (see comment [a]). Values for the remaining paradigms are based on Affymetri
marked (b). Omarks TSC data whose statistical signiﬁcance was recapitulated in qPCR a
Pparg-null placentas, further clustered within these partitions according to signiﬁcanc
according to their FC in Pparg-null placentas.
Gene Pparg-null placentas
qPCR (FC; P)
Rxra-null placentas
Affy (FC; q)
Rosi effect in WT TS
Affy (FC; q)
Muc1 14.36; 0.000 3.13; 0.000 þ2.20; 0.014 O
Csh2 3.79; 0.001 2.32; 0.000 1.64; 0.010b,c O
Tmem166 3.52; 0.000 2.01; 0.000 þ1.34; 0.037
Grtp1 2.63; 0.001 1.76; 0.000 þ1.44; 0.016
Lepr 2.40; 0.000 2.14; 0.000 þ3.70; 0.006 O
Ldhb 2.37; 0.000 3.13; 0.000 þ1.70; 0.014 O
Ctsr 2.24; 0.024 2.45; 0.000 þ2.68; 0.010 O
Adck5 2.18; 0.001 1.56; 0.000 þ1.86; 0.010 O
Pcx 2.17; 0.002 1.72; 0.000 þ1.52; 0.016 O
Als2cl 1.99; 0.004 1.59; 0.000 þ1.57; 0.014 O
Tsc22d3 1.90; 0.006 2.25; 0.000 þ1.45; 0.020 O
Tgfb3 1.86; 0.001 1.81; 0.000 þ1.32; 0.045
Dcakd 1.62; 0.000 1.68; 0.000 þ1.51; 0.014 O
Nostrin 1.34; 0.019 1.34; 0.000 þ1.63; 0.026 O
Hsd17b11 1.82; 0.022 1.86; 0.000 þ1.39; 0.022
Limd2 1.76; 0.005 1.59; 0.000 þ1.67; 0.014 O
Prdx4 1.58; 0.000a 1.53; 0.000 þ1.54; 0.014
Nt5c2 1.45; 0.010 1.74; 0.000 þ1.99; 0.010 O
Sgk2 4.96; 0.000 2.12; 0.000 þ1.58; 0.003b O
Rdh12 2.93; 0.002 1.60; 0.000 þ1.42; 0.022
Hrct1 2.27; 0.024 2.35; 0.000 þ1.46; 0.018 O
Rnd2 2.04; 0.001 1.49; 0.000 þ1.41; 0.022 O
Tmem125 2.00; 0.001 1.62; 0.000 þ1.54; 0.014 O
Lifr 2.00; 0.000 1.55; 0.001 þ1.67; 0.015 O
Mertk 1.79; 0.000 1.52; 0.000 þ1.57; 0.003b O
Vash2 1.69; 0.001 1.55; 0.002 1.31; 0.024c
Nt5e 1.61; 0.016 1.72; 0.001 þ1.31; 0.039
Chst13 1.45; 0.009 2.02; 0.000 þ1.36; 0.012b
Fam83d 1.73; 0.008 1.98; 0.000 þ2.49; 0.006 O
Arhgap18 2.23; 0.000 1.62; 0.000 þ1.71; 0.020 O
L1td1 þ2.21; 0.000 þ1.66; 0.000 1.49; 0.016
Pthlh þ1.81; 0.000 þ2.37; 0.000 þ1.63; 0.036c
Hbegf þ1.52; 0.003 þ1.33; 0.002 1.36; 0.023
Pkdcc þ1.72; 0.018 þ1.71; 0.001 2.05; 0.002b
Atp2a3 þ2.54; 0.000 þ1.46; 0.001 1.49; 0.014b
a No adequate qPCR conditions were identiﬁed Prdx4; ND—No data.
b FC and/or P insigniﬁcant on day 4; day 2 data (shown) are signiﬁcant.
c Statistically signiﬁcant FC values, yet discordant regulation compared to Pparg-nu
d Borderline values in Ppargþ / or Ncoa6-null placentas: either slightly below the
e FC and/or P values are markedly insigniﬁcant in Ppargþ / or Ncoa6-null placentaPparg-null TSC did not exhibit consistent aberrations in the
expression of other prototypic markers of the primary trophoblast
lineages (see Table S2). Thus, WT and Pparg-null TSC provide a
robust and malleable system, which retains key developmental
features of trophoblasts without being muddled by other placental
cell populations.
Because expression of canonical PPARg targets is expected to
respond to both genetic and pharmacological manipulations of
PPARg, we screened for reproducible effects of both Pparg deﬁciency
and PPARg agonists among all ﬁve TSC lines. Accordingly, we proﬁled
gene expression in ﬁve lines two and four days after induction of
differentiation by withdrawal of FGF4, heparin and conditioned
media, both in the presence and absence of Rosi. Conﬁdence in the
dataset was provided by: (i) high Pparg expression in all WT TSC and
practically no expression in both Pparg-null TSC lines; (ii) down-
regulation of Pparg by Rosi in each of the three WT lines, as observed
previously (Shalom-Barak et al., 2004); (iii) induction of Muc1 and its
further stimulation by Rosi during differentiation of all three WT, but
none of the Pparg-null TSC lines (not shown).se expression was signiﬁcantly altered in each of Pparg-null placentas, Rxra-null
listed for all genes in each of these systems, as well as in Ppargþ / and Ncoa6-null
ed as well. Values for Pparg-null and Ppargþ / placentas are based on qPCR, except
x microarray data. TSC values are from the 4th day of differentiation, except values
nalyses. Genes were partitioned according to down-regulation vs. up-regulation in
e patterns in Ppargþ / and Ncoa6-null placentas, and sorted within each cluster
C Pparg-null TSC
Affy (FC; q)
Ppargþ / placentas
qPCR (FC; P; % of FC-null)
Ncoa6-null placentas
Affy (FC; q)
2.40; 0.020 1.71; 0.001; 45 1.79; 0.004
23.48; 0.004 O 1.90; 0.001; 64 3.36; 0.001
2.11; 0.029 1.56; 0.005; 50 2.10; 0.000
2.33; 0.015 O 1.82; 0.041; 73 1.42; 0.018
2.64; 0.015 O 1.63; 0.007; 66 1.69; 0.012
7.13; 0.004 O 1.29; 0.024; 38 2.71; 0.001
6.95; 0.005 O 1.52; 0.020; 61 1.68; 0.032
1.69; 0.035 1.45; 0.013; 58 1.48; 0.002
1.58; 0.040 O 1.51; 0.011; 63 1.98; 0.000
2.12; 0.023 1.21; 0.015; 35 2.85; 0.000
6.74; 0.012 1.41; 0.047; 61 2.00; 0.011
1.58; 0.045 1.32; 0.041; 52 3.02; 0.000
1.96; 0.035 O 1.30; 0.004; 60 1.66; 0.001
3.47; 0.021 1.21; 0.010; 69 1.28; 0.011d
3.74; 0.009 1.43; 0.106; 67d 1.99; 0.000
3.89; 0.005 O 1.17; 0.072; 33d 1.61; 0.002
1.84; 0.017 NDa,d 1.31; 0.009
1.75; 0.025 O 1.18; 0.087; 50d 1.54; 0.015
2.42; 0.034 þ1.13; 0.233; 16e 1.33; 0.024
2.53; 0.034 O 1.18; 0.284; 23e 1.52; 0.009
1.55; 0.009 O 1.01; 0.467; 2e 3.17; 0.000
1.82; 0.037 1.17; 0.125; 29e 1.81; 0.003
2.11; 0.049 1.12; 0.143; 22e 1.76; 0.001
4.70; 0.008 1.02; 0.470; 3e 1.57; 0.006
6.13; 0.010 1.11; 0.146; 23e 1.41; 0.045
þ1.86; 0.035c 1.11; 0.084; 25e 2.70; 0.000
3.62; 0.020 1.00; 0.496; 1e 2.59; 0.003
1.67; 0.035 þ1.09; 0.169; 28e 2.04; 0.000
1.95; 0.020 O 1.13; 0.238; 27e 1.28; 0.004d
4.73; 0.004 O 1.06; 0.281; 10e 1.07; 0.374e
þ1.93; 0.006 þ1.80; 0.003; 67 þ1.53; 0.014
6.09; 0.005c O þ1.34; 0.000; 42 þ4.98; 0.000
þ2.19; 0.005 O þ1.12; 0.008; 24d þ1.01; 0.499e
þ2.06; 0.022 þ1.08; 0.147; 11e 1.58; 0.009c
þ2.36; 0.027 þ1.05; 0.374; 3e þ1.41; 0.005
ll placentas.
FC threshold and Po0.05 or exceeding the FC threshold and Pr0.1.
s.
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genes among the ﬁve TSC lines yielded prohibitive false discovery
rates when all transcripts were analyzed. Considering the limited
physiological relevance of genes whose expression does not change
in vivo, we therefore ﬁltered the test data to the 784 probe sets
that passed the differential expression threshold in Pparg-null
placentas. These were subject to three primary analyses, with FC
and q cutoffs of 41.3 and o0.05, respectively: (i) Responses to
stimulation of PPARg by Rosi, determined by pair-wise compar-
isons within each of the three WT TSC lines, to circumvent the
variegated basal expression of individual genes among the lines.
(ii) Effects of PPARg deﬁciency, determined by variance analysis of
the three untreated WT TSC lines vs. the two Rosi-treated Pparg-
null ones. (iii) Compound effects of the two variables, determined
by variance analysis of Rosi-treated WT vs. Pparg-null TSC. The
power of the latter analysis is evident in the discovery of 99
additional differential transcripts that fell below the signiﬁcance
thresholds of the singular PPARg stimulation or deﬁciency criteria.
The heat map in Fig. 3A breaks down the entire 784 probe set
ﬁeld. It demonstrates that transcripts induced by Rosi in WT TSC and/
or down-regulated in Pparg-null TSC adhered with high consistency
to three reliability criteria: (i) Concordant direction with in vivo
regulation, ie down-regulation in Pparg-null placentas. (ii) Temporal
continuity, i.e., maintenance of the expression differential from
day 2 to day 4. Importantly, only eight transcripts were signiﬁ-
cantly different between WT and Pparg-null TSC on day 2, likely
due to slow cumulative effect of PPARg that was further com-
pounded by variation between the cell lines. However, four days
of differentiation unveiled 146 signiﬁcant changes between WT
and Pparg-null TSC lines, including all eight discovered on day 2.
(iii) Recapitulation of the responses to Rosi or PPARg deﬁciency
alone in the compound difference between Rosi-treated WT and
Pparg-null TSC. In contrast, transcripts that were signiﬁcantlyFig. 4. Temporal patterns in of PPARg-regulated genes in TSC. Expression of six
prototypic PPARg-dependent genes during differentiation of the WT TSC line GFP-
Trf (Solid lines, squares) and the Pparg-null TSC line gy09 (dashed lines, circles) in
the absence (empty squares/circles) or presence of Rosi (ﬁlled squares/circles).
Each qPCR measurement was performed in triplicates, normalized to the Dazap1
gene and transformed to linear scale by the DDCt method. Expression at day 4 in
the presence of Rosi was assigned a relative value of 1.0.suppressed by Rosi were the least consistent with these criteria:
36–41% were down-regulated in Pparg-null placentas in vivo
(discordant regulation), 57% lost their suppressed status from
day 2 to day 4 (temporal discontinuity), and 41% fell short of the
compound differential cutoff. These incongruities reduce the
technical conﬁdence in such readouts, and in conjunction with
the prototypic transactivation properties of Rosi-stimulated
PPARg, in the reliability of purported Rosi suppression events.
Fig. 3B hones in on all probe sets that passed the differential
expression thresholds of both PPARg deﬁciency and pharmacolo-
gical stimulation in TSC. This cross-section of genes reveals
enrichment for RXRa-dependent genes (64% vs. 40% in the
starting gene pool) and for PPARg-induced genes (53 vs. 12,
compared to 481 vs. 303 in the starting dataset), reiterating the
features of prototypic PPARg targets.
Table 1 distills these data to the 35 genes that also changed
signiﬁcantly in Rxra-null placentas, further listing their responses
to placental Pparg haploinsufﬁciency and Ncoa6 deﬁciency.
At least 27 of the 30 positively regulated genes (90%) were
signiﬁcantly down-regulated in Ncoa6-null placentas, up from
43% and 63% of the genes showing down-regulation in Pparg-null
placentas alone or both Pparg-null and Rxra-null placentas,
respectively (see Fig. 1D). In addition, three of the ﬁve negatively
regulated genes were also up-regulated in Ncoa6-null placentas.
This progressive enrichment links the likelihood that a gene
abided by all canonical PPARg-dependence criteria to its depen-
dence on NCOA6. In contrast, genes with PPARg dosage sensitivity
were not enriched compared to the broader pool of genes that
changed in Pparg-null placentas irrespective of other criteria
(Table S4), questioning the reliability of dosage sensitivity as a
consistent staple of canonical PPARg targets.Diverse temporal and spatial patterns of PPARg-dependent
trophoblast genes
To analyze the timing and topology of PPARg action during
placental development, we interrogated the in vivo and in vitro
expression patterns of representative genes that emerged from
the analyses above. Supplemental Fig. S1 shows single qPCR
measurements of 51 such genes throughout differentiation of
the WT and Pparg-null TSC lines in the presence and absence of
Rosi. Genes with representative expression prototypes were
reconﬁrmed in one WT (GFP-Trf) and one Pparg-null TSC line by
triplicate qPCR (Fig. 4). Several prototypic patterns emerged:(i) Canonical induction (Fig. S1A–C): none-to-low expression in
undifferentiated TSC, followed by incremental induction as
early as one day or as late as four days from the onset of
differentiation in WT but not Pparg-null TSC. Rosi typically
enhanced such genes in WT TSC, and some genes could not
attain signiﬁcant expression in its absence. Prototypic exam-
ples shown are Prolactin Receptor (Prlr), Muc1, and Leptin
Receptor (Lepr) (Fig. 4A–C).(ii) A ‘‘bowl-shaped’’ response (Fig. S1D): considerable, PPARg-
independent expression in undifferentiated TSC, followed by
a signiﬁcant drop during early differentiation, then resur-
gence and further stimulation by Rosi in WT, but not Pparg-
null TSC. Variations of this pattern were exhibited by twelve
of the tested genes, most of which encode metabolic
functions. Shown are Lactate Dehydrogenase B (Ldhb) and
Pyruvate Carboxylase (Pcx) (Fig. 4D–E).(iii) Biphasic induction (Fig. S1E): PPARg-dependent or indepen-
dent up-regulation within one day of differentiation, down-
regulation by the second day, and a subsequent PPARg-
dependent induction towards the fourth day of differentiation.
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(Fig. S1F), represented in Fig. 4F by Heparin-Binding EGF-like
Growth Factor (Hbegf).Placental distribution and PPARg-dependence patterns exhib-
ited marked variability as well; respective genotypes were deter-
mine by the expression of Pparg and/or lacZ (Fig. 5A–D):(i) Muc1 was expressed in a PPARg-dependent fashion in the
trophoblast layer ﬂanking the labyrinthine maternal blood
pools, as previously shown (Fig. 5E and F; Shalom-Barak
et al., 2004).(ii) Serum and Glucocorticoid-Induced Kinase 2 (Sgk2) was
limited to a perichorionic trophoblast layer and absent from
Pparg-null placentas (Fig. 5G and H).(iii) Carcinoembryonic Antigen-Related Cell Adhesion Molecule
11 (Ceacam11), which registered the strongest decline of any
gene in Pparg-null placentas (see Table S4), was expressed in
a PPARg-dependent fashion in scattered cells at the distal
part of the SpT layer (Fig. 5I and J; compare spatial distribu-
tion to the canonical pan-SpT marker Tpbpa, Fig. 5K and L).
Later in development Ceacam11-expressing cells populate
parts of the SpT, and are distinct from glycogen trophoblasts
(Kataoka et al., 2000 and data not shown).(iv) Ldhb was expressed evenly throughout the chorion and
trophoblast giant cells (TGC), as well as the labyrinth and
SpT layers of WT placentas (Fig. 5M and O; arrows in 5O
point to labyrinthine and SpT expression; see Muc1 in 5E for
localization of the labyrinth and Tpbpa in 5K for the SpT).
In Pparg-null placentas, its expression was enhanced in the
chorion and TGC, but wiped out in the labyrinthine and SpT
zones (Fig. 5N and P), conceivably driving the net reduction
of 2.5 indicated by the underlying qPCR data.(v) In WT placentas cathepsin R (Ctsr) was robustly expressed in
TGC, as well as in the SpT and around maternal blood pools in
the labyrinth (Fig. 5Q and S; arrows in 5S pinpoint labyr-
inthine expression), as previously described (Simmons et al.,
2007). Pparg-null placentas retained Ctsr expression in SpT
and TGC, while completely losing it in the labyrinth (Fig. 5R
and T), sufﬁcing for a 2.2-fold lower expression overall, as
indicated by qPCR.Fig. 5. Spatial distribution of placental PPARg-dependent genes. Serial sections
of E9.5 WT (left panels) and Pparg-null concepti (right) were hybridized with
antisense RNA probes for Pparg (A)–(B), lacZ (C)–(D), Muc1 (E)–(F), Sgk2 (G)–(H),
Ceacam11 (I)–(J), Tpbpa (K)–(L) Ldhb ((M)–(P); arrows in O: expression in the
labyrinth and SpT, absent in Pparg-null placentas [P]), and Ctsr ((Q)–(T); arrows in
S: expression around maternal blood pools in the labyrinth, absent in Pparg-null
placentas [T]). Scale bar 500 mm, except O,P,S,T 200 mm.Combined, these analyses demonstrate that PPARg regulates
diverse genes at distinct stages of differentiation and in various
trophoblast lineages.
Ldhb is a target of PPARg in trophoblasts
To gain insights into the placental activities of PPARg, we
sought functional themes among either the distilled targets in
Table 1 or the larger set of all genes that changed in Pparg-null
and Rxra-null placentas. Several patterns emerged: (i) PPARg
enhanced the expression of multiple rodent-speciﬁc, lineage-
speciﬁc placental genes, including Ctsr, Prl2b1 (Prlpk), Prl3b1
(Csh2), Prl7b1 (Prlpn), and Ceacam11. (ii) PPARg up-regulated
multiple hormones or their receptors, particularly ones that
control energy storage and metabolism, including Ghrh, Prlr, Lepr,
Gcgr, Pthlh, and the mouse-speciﬁc prolactin family members
mentioned above (Prl2b1, 3b1 and 7b1). (iii) PPARg induced genes
whose products are either known or logically relate to inter-
mediary metabolism, including Ldhb, Pcx, Dgat1, Angptl4, Hsd17b4,
Hsd17b11, and Dcakd.
Pcx, Dgat1 and Angptl4 have been previously implicated as
direct PPARg targets in adipocytes and/or macrophages
(Jitrapakdee et al., 2005; Ruan et al., 2003; Koliwad et al., 2010;
Yoon et al., 2000), and our ﬁndings extend these regulatoryrelationships to trophoblasts. Of the remaining genes, four
reasons compelled us to focus on Ldhb. First, its strong abidance
by each of the PPARg dependence criteria and its dependence on
NCOA6 were highly consistent with a key PPARg-dependent
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expressed in adipocytes in vivo and in vitro, and is refractory to
either PPARg stimulation or deﬁciency in differentiated 3T3-L1 cells
(S. Kim and YB, unpublished data), indicating that its dependence on
PPARg is tissue-speciﬁc. Third, follow-up qPCR analyses singled out
Ldhb as the most up-regulated out of eleven PPARg target candidates
in placentas from Rosi-treated pregnant WT mice (Fig. 6A). Last, age-
old studies that inferred the preference of LDHB for conversion of
lactate to pyruvate (Cahn et al., 1962; Dawson et al., 1964) imply
tandem synergy with the co-regulated PCX, which catalyzes carbox-
ylation of pyruvate into oxaloacetate.
A 2.7 kb genomic fragment encompassing the proximal
promoter and ﬁrst intron of Ldhb contains three PPRE-like
elements (RE1, RE2, RE3; Fig. 6B). This fragment drove a strong,
RXRa-dependent response of a luciferase reporter to PPARg and
Rosi, and much weaker responses to PPARa or PPARd and their
cognate agonists (Fig. 6C). The observed transcriptional activity
was split between the proximal promoter, containing RE1, and
the ﬁrst intron, containing RE2 and RE3 (Fig. 6D). ChIP analysis
indicated that RE1 and RE3 interact closely with PPARg in Rosi-
treated differentiated TSC; RE2 exhibited no detectable binding
(Fig. 6E).
A complex pattern of unique and redundant contributions to the
PPARg response of Ldhb was revealed by mutating the putative
PPREs, alone and in combination, in the contexts of the full 2.7 kb
and the disparate promoter and intronic sub-fragments (see Fig. 6B
for the mutant sequences). Mutating all three PPREs reduced the
PPARg response of the full promoter fragment by 40% (Fig. 6F, M1/
2/3). This indicated the importance of at least some of the PPREs, but
also the contribution of additional promoter elements, either non-
PPREs or non-obvious ones, to the PPARg response. Such coopera-
tion between PPRE-like and non-PPRE elements recapitulates our
previous ﬁndings on the regulation of the Muc1 promoter by PPARg
(Shalom-Barak et al., 2004). It suggests that PPARg utilizes alter-
native, non DNA-binding mechanisms to engage with and activate
its native targets even when direct DNA binding is prohibited.
Similar evidence of cooperation between PPREs and non-PPREs
came to light when RE1 was mutated in the context of the proximal
promoter fragment (Fig. 6G, M1), as well as when both RE2 and RE3
were mutated within the intronic fragment (Fig. 6G, M2/3). Con-
sistent with the ChIP data, mutations of individual PPREs revealed
signiﬁcant, albeit modest contributions of RE1 and RE3, but com-
plete dispensability of RE2 for activation of the full fragment when
the other two REs remained intact (Fig. 6F, M1, M2 and M3).
However, RE2 seems to function as a backup PPRE. Thus, within
the 2.7 kb fragment both RE2 and RE3 were dispensable when RE1
was intact (Fig. 6F, M2/3), but loss of either alongside RE1 was
functionally equivalent to the loss of all three PPREs (Fig. 6F, M1/2
and M1/3 vs. M1/2/3). In contrast, although elimination of both RE2
and RE3 blunted the response of the intronic fragment (Fig. 6G, M2/
3), either was dispensable for PPARg responsiveness in the presence
of the other (Fig. 6G, M2 and M3).
These combinatorial regulatory contributions of the three
PPREs alongside non-PPRE sequences strongly indicate that the
regulation of Ldhb by PPARg is remote from promiscuous. Added
to our microarray, qPCR and in situ hybridization results, these
analyses implicate Ldhb as an important part of a PPARg-
controlled metabolic program in differentiated trophoblasts.Discussion
Conceptual strengths and methodological limitations
Placental PPARg function cannot be readily deduced from the
complex phenotype of Pparg-null placentas or the extensiveknowledge of PPARg function in other tissues. Our rigorous
screens aimed at overcoming this hurdle by pinpointing high-
conﬁdence downstream targets of PPARg in trophoblasts. We
integrated the four non-redundant PPARg-dependence para-
digms of altered expression in Pparg-null placentas, Rxra-null
placentas, Rosi-treated WT TSC, and Pparg-null TSC, surmising
that any genuine PPARg target should abide by each of these
criteria. We further buttressed robustness by careful biological
replications within each of these categories. Speciﬁcally, in
whole placentas we reined in random discoveries by comparing
three pools of three WT to three pools of three Pparg-null or
Rxra-null placentas, which normalized both placenta-to-
placenta variation and uneven sample contamination with
peri-placental tissues. In TSC, we aimed for robustness by
aligning two WT lines from other laboratories with one WT
and two Pparg-null lines that we generated for this study. While
each of these lines exhibited basic cellular and molecular
characteristics of TSC, their global gene expression patterns,
levels and kinetics were markedly heterogeneous even within
same-genotype groups. Because no single TSC line could be
deemed more representative than others, we circumvented this
limitation by centering on genes that were differentially
expressed in Pparg-null placentas. This retained the robustness
offered by the multiple TSC lines, while focusing on genes with
immediate in vivo relevance. In additional post-hoc qPCR ana-
lyses that tested effects of PPARg dosage in Ppargþ / placentas,
less than 50% of all genes tested passed a liberal dosage
sensitivity benchmark, and this ratio was not improved among
genes that abided by all paradigms. While the primary reason is
conceivably the statistically ﬁckle nature of the rather minute
differential anticipated of most of these genes, PPARg dosage
sensitivity could not be reasonably applied as an exclusion
criterion, and had solely conﬁrmatory value.
A critical component in paradigm integration was the choice of
FC and q-value thresholds. To contain false negative calls while
ensuring that only genuinely expressed genes impacted FDR
without compromising exclusion of false positive data, we nar-
rowed the viable data ﬁelds by omitting the all probe sets that
scored ‘Absent’ in all samples by MAS5.0 (see Fig. S2 and legend
for a detailed rationale). We then chose the cutoffs of 1.3
change and qo0.05. Our subsequent qPCR analyses conﬁrmed
that false discovery was indeed contained at{5% (see Table S4);
however, we suspect that quite a few true PPARg targets may
have still been excluded, including: (i) Genes that failed just a
single criterion. For instance, potential targets may have exhibited
prohibitive FDR in biological replications in cases of naturally
variegated expression. (ii) Genes with no to sub-detectable
expression in vitro. For example, Ceacam11, which exhibited the
strongest differential in vivo, was excluded due to its complete
absence from differentiated TSC. Another example is the Gcgr
gene, which we conﬁrmed as a PPARg target during a parallel
research pursuit (Shalom-Barak et al., in preparation). Despite a
20-fold lower expression in Pparg-null placentas (q{ 0.05),
Gcgrmissed our cut because its expression in TSC was too close to
background in Affymetrix microarrays; targeted qPCR analyses
later conﬁrmed its PPARg response in TSC. (iii) Genes with
transient PPARg dependence outside the analyzed time points,
e.g., earlier than E9.5 or prior to the second day of TSC
differentiation.
While at present we have no foolproof statistical method for
overcoming the listed limitations on a systems scale, a potential
future approach could be the development and meta-implementation
of a reliable algorithm for FDR calculation in intersecting datasets. For
now, to avoid muddying our initial insights with false positive
identiﬁcations, our analysis centered on genes that abided stringently
by each of the aforementioned criteria.
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A considerable 40% of the gene expression changes in Pparg-
null placentas recur in Rxra-null placentas, consistent with pre-
vious studies that implicated RXRa as the major heterodimeric
partner of PPARg in the tissue (Sapin et al., 1997; Barak et al.,
1999). The higher percentage of RXRa dependence (64%) among
transcripts that responded to PPARg in TSC buttresses this
assertion. Considering genome-wide interaction studies that
demonstrated RXRa occupancy of nearly all PPARg genomic
binding sites in adipocytes and macrophages (Nielsen et al.,
2008; Lefterova et al., 2008, 2010), the remaining non-overlap is
probably not due to RXR-independent functions of PPARg. A more
likely explanation is the unique phenotypic aspects of Pparg-null
placentas, such as their terminal failure, which are averted in
Rxra-null placentas via functional redundancy with basal levels of
RXRb (Wendling et al., 1999). Redundancy could be indiscrimi-
nate across PPARg target promoters, such that residual RXRb
sustains sufﬁcient expression of essential targets (Sapin et al.,
1997). Alternatively, some PPARg targets could be RXR isoform-
speciﬁc, with RXRa-speciﬁc targets severely affected and essen-
tial RXRb-speciﬁc targets largely unchanged in Rxra-null placen-
tas. Future assessment of these scenarios would require either
direct expression data from Rxrb-null and Rxra/b compound null
placentas or genome-wide placental DNA-binding screens of
PPARg in WT and Rxra-null placentas. The hundreds of genes
whose expression is affected in Rxra-null, but not Pparg-null
placentas likely represent direct and indirect targets of other
RXR-dependent nuclear receptors, such as PPARd, LXRs and RARs.
Although PPARg has been strongly implicated in corepressor
interaction and gene silencing akin to the related RAR and TR,
mechanistic details and speciﬁc targets of PPARg-mediated
repression are rather ill-deﬁned (Cohen, 2006). Our data offer a
systems perspective on the issue. In whole placentas, 303 tran-
scripts were up-regulated subsequent to PPARg deﬁciency, com-
pared to 481 down-regulated ones. However, in TSC, where one
would expect a proportionate number of positive and negative
direct targets, this ratio declined 3.6-fold (9/303 vs. 52/481).
Moreover, the canonical paradigm for direct repression by nuclear
receptors involves silencing in the absence of ligand and activa-
tion in its presence (Glass and Rosenfeld, 2000). By the same
token, direct repression targets of PPARg should conceivably be
up-regulated in Rosi-treated WT TSC. Yet, all nine genes up-
regulated in Pparg-null TSC were down-regulated by Rosi, incon-
sistent with repression by DNA-bound PPARg. Instead, these
genes are probably repressed either secondary to PPARg action
or through a previously proposed mechanism of ligand-
dependent binding and stabilization of corepressor complexes
anchored to DNA through other transcription factors (Pascual
et al., 2005).
This study provided critical assessment of the purported
contributions of the transcriptional coactivators PBP (MED1) andFig. 6. Regulation of Ldhb by PPARg. (A) RT-qPCR of RNA from WT E18.5 embryos from
are expressed as box plots showing median value, upper and lower quartiles, range, an
according to Mann–Whitney test. (B) Structures of the full-length genomic Ldhb frag
positions of Exons 1 and 2 and the three PPRE-like elements (RE1, RE2 and RE3), includ
into each (M1, M2, M3). Inverted lettering of RE1 and RE2 symbolizes their opposi
fragments were constructed into a promoterless pGL3-Basic vector, whereas the intro
pGL3-Promoter vector. (C) CV1 cells were transfected with a luciferase reporter driven b
the presence or absence of the cognate ligands, as indicated (1 mM Rosi, 5 mM Wy14643
combinations of PPARg and RXRa were co-transfected with the three different Ldhb pr
Rosi, as labeled. (E) ChIP analysis of PPARg binding to each of the three PPREs in TSC d
(left panel) or 1% of the input DNA (right) are shown for: Pparg-null TSC precipitated wit
or aP (lane 3). (F) and (G) Cells were transfected with full-length 2.7 kb Ldhb promoter
designated native (WT) or mutant PPRE combinations, RXRa (all wells), PPARg as
differences of PPARgþRosi-stimulated reporter activity compared to the WT fragment.
was measured 48 h post-transfection and normalized to b-galactosidase activity of co-AIB3 (NCOA6) to placental gene regulation by PPARg (Zhu et al.,
2000; Kuang et al., 2002). MED1 affected the expression of
surprisingly few placental genes at E9.5, only one of which,
exhibiting a marginal differential response, was weakly PPARg-
and RXRa-dependent. These ﬁndings warrant thorough reevalua-
tion of the Med1-null placental phenotype and its relationship to
PPARg function in this tissue. In contrast, NCOA6 deﬁciency
affected over 2500 transcripts in E9.5 placentas, including 63%
of those that were down-regulated in both Pparg-null and Rxra-
null placentas and 90% of the genes that abided by all primary
criteria of positive regulation by PPARg (see Table 1). These
observations, and the remarkable phenotypic similarity between
Pparg-null and Ncoa6-null placentas, suggest that the
target(s) accounting for the essential placental functions of PPARg
are part of the NCOA6-coactivated contingent.PPARg function in the placenta
With a few notable exceptions, the majority of placental
PPARg-dependent genes have not been described as PPARg
targets outside this tissue. Moreover, within the placenta itself
PPARg-dependent genes are spatially and temporally variegated,
with distinct expression patterns in different subsets of tropho-
blast lineages and different induction kinetics during TSC differ-
entiation. This diversity suggests that the unique subset of
trophoblast PPARg target genes is further partitioned into distinct
spatiotemporal target combinations within the placenta.
Some of these expression patterns in their own right offer
potential leads into placental PPARg function. For example:
(i) The narrow perichorionic expression of Sgk2 and its PPARg-
dependent induction within one day of TSC differentiation sug-
gest that PPARg acts very early during trophoblast differentiation.
(ii) The rodent-speciﬁc Ceacam11, which is expressed in a novel
subset of SpT cells, is the single most down-regulated gene in
Pparg-null, Rxra-null and Ncoa6-null placentas, as well as in the
phenotypically similar aV-intergin (Itgav)-null placentas (Bader
et al., 1998; data not shown). No other PPARg-dependent gene is
affected in Itgav-null placentas, suggesting that either Ceacam11
or, more likely, its host trophoblast lineage is at the crux of
placental PPARg and aV-integrin signaling in rodents. (iii) Simi-
larly, PPARg-dependent expression of the labyrinthine sinusoidal
trophoblasts-speciﬁc Prl3b1 and Ctsr (Simmons et al., 2007) could
be either a product of direct regulation or a reﬂection of key roles
of PPARg in differentiation or survival of the sinusoidal lineage.
Such effects on placental lineage decisions may explain the
pleiotropic outcomes of PPARg deﬁciency. Notably, the insignif-
icant expression changes of classical markers of the labyrinth, SpT
and TGC in Pparg-null placentas suggest that if PPARg affects any
placental lineage decisions, these are limited to specialized line-
age subtypes.pregnant mice untreated () or treated with Rosi (þ) from E10.5 to E18.5. Data
d outliers. Ctrl: n¼23; Rosi: n¼24. Asterisks—statistically signiﬁcant differences
ment (promoterþ intron 1, top) and its two sub-fragments. Shown are relative
ing their native sequences and the sequences of inactivating mutations introduced
te orientation relative to Ldhb transcription. The proximal promoter-containing
nic fragment was placed upstream of an SV40 promoter-driven luciferase of the
y the full-length Ldhb fragment, RXRa and the indicated combinations of PPARs, in
, and 1 mM L165041 for PPARg, PPARa, and PPARd, respectively). (D) The indicated
omoter fragment-driven luciferase constructs, in the absence or presence of 1 mM
ifferentiated for 4 day in the presence of Rosi. PCR-ampliﬁed Immunoprecipitated
h anti-PPARg antibody (aP, lane 1) and WT TSC with preimmune serum (PI, lane 2)
fragments (F) or the disparate promoter and intronic fragments (G) harboring the
indicated, and 1 mM Rosi where labeled. Asterisks mark statistically signiﬁcant
All assays in (C), (D), (F) and (G) were performed in triplicates. Luciferase activities
transfected CMV-lacZ. RLU—Relative luminescence.
T. Shalom-Barak et al. / Developmental Biology 372 (2012) 143–155154The cohort of metabolic PPARg target genes, represented by Ldhb
and Pcx, provides other exciting insights. First, these genes exhibit
substantial PPARg-independent expression in undifferentiated TSC,
suppression during early differentiation, and resurgence in WT, but
not Pparg-null cells. This ‘‘bowl-shaped’’ pattern suggests that both
stem and differentiated trophoblasts share a core metabolic pro-
gram, but regulate it through mutually exclusive mechanisms,
switching from dependence on stem-speciﬁc factors in TSC to
obligatory PPARg dependence upon their differentiation. PPARg-
independent expression of Ldhb in the stem cell-rich chorion and its
PPARg-dependence in the differentiated labyrinth and SpT is con-
ceivably the spatial analog of this pattern. There is an apparent
contradiction between the PPARg-independent expression of Ldhb
in placental TGC and its PPARg-dependence in differentiated TSC
cultures, which are dominated by TGC-like cells. This discrepancy
can be settled by reconsidering the possibility that these TGC-like
cells in culture are more akin to labyrinthine sinusoidal cells, which
would align with the aforementioned idea that PPARg regulates
gene expression in this lineage.
Second, the enzymatic functions of targets that fall into this
regulatory category lead us to conjecture a unique placental
metabolic cascade, illustrated in Fig. 7. The pivot point in this
hypothetical program is pyruvate carboxylase, the product of Pcx,
which converts pyruvate to oxaloacetate (OAA). OAA is a common
precursor for multiple key metabolic pathways, including gluco-
neogenesis, anaplerotic replenishment of the tricarboxylic acid
(TCA) cycle of oxidative respiration, and lipogenesis (Jitrapakdee
et al., 2008). Of these, the most plausible conjecture is that
PPARg-regulated PCX catalyzes OAA formation in trophoblasts
for the same primary purpose as in adipocytes, i.e., to prime de
novo fatty acid synthesis (Jitrapakdee et al., 2005; Ballard and
Hanson, 1967; Kajimoto et al., 2005). The similar regulatory
pattern of Dgat1, which is the last and rate-limiting step in
triglyceride synthesis (Yen et al., 2008), should maintain a
forward equilibrium by utilizing the resulting fatty acids,
implicating PPARg in integrated control of placental lipogenesis.
Therefore, and considering the glaring lack of evidence for PPARg-
regulated lipid uptake or binding genes in our screens, even with
relaxed discovery criteria, impaired fatty acid synthesis is a likely
explanation for the extreme lipid depletion of Pparg- and Rxra-
null placentas (Barak et al., 1999; Sapin et al., 1997). The novel
dephospho-CoA Kinase homolog Dcakd may keep this putativeFig. 7. A model for PPARg-regulated placental metabolism.Multiple PPARg-regulated
in an integrated, putative placental metabolic pathway. PPARg-regulated genes
CoA—Coenzyme A; DAG—Diacylglycerol; FA—Fatty scids; LPL—Lipoprotein Lipase; PEcascade rolling by maintaining a steady supply of coenzyme A,
which keeps being consumed as a skeleton for the resultant fatty
acyl chains. Finally, we hypothesize that unlike in adipocytes, the
trophoblast PPARg-driven lipogenic program initiates with lactate
dehydrogenase B (LDHB). LDHB differs from the related LDHA in
its kinetic and thermodynamic preferences for lactate to pyruvate
conversion (Cahn et al., 1962; Dawson et al., 1964), invoking a
PPARg-coregulated enzymatic tandem of LDHB and PCX at the
head of a pathway that recycles lactate into triglycerides. Integra-
tion of lactate into this cascade is in line with emerging evidence
that other cells are able to efﬁciently utilize it as an alternate fuel
source, as is the case with muscle during endurance exercise or
neurons during hypoglycemia (Gladden, 2000; Wyss et al., 2011).
Conceivably, the placenta may have adopted a similar program as
a thrift mechanism that taps into the copious lactate waste hauled
in by incoming maternal erythrocytes, where it is the dead-end
product of housekeeping glycolysis (Bartlett, 1959). Notably, the
absence of clinical symptoms in LDHB-deﬁcient patients
(Takatani et al., 2001) and the strictly postnatal symptoms of
PC-deﬁcient infants (Marin-Valencia et al., 2010) indicate that
individual components of this program may be superﬂuous for
placental development per se. Irrespective of whether this reﬂects
dispensability, redundancy, or alternative metabolic pathways,
the remarkable co-regulation of this gene network is highly
suggestive of its primary signiﬁcance in the placenta on an
evolutionary scale.
On a ﬁnal note, the absence of signiﬁcant changes in canonical
regulators of differentiation or development is surprising given
the striking developmental phenotype of Pparg-null placentas.
While one cannot formally exclude roles of novel genes from this
screen in such tasks, we are increasingly compelled to consider
the possibility that trophoblast differentiation is tied to successful
execution of their unique metabolism. Conceivably, such link
could be in the form of either metabolic fuel requirements or
intermediate metabolites with dedicated signaling functions.Acknowledgments
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